Chinook Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €5.29M -88.1% -€159.25M +82.2% -3,012.6% -28 pp -€99.91M +14.8% -1,890.1% -17 pp
    €44.53M +6,142.4% -€87.38M +24.1% -196.2% +97 pp -€87.01M +83.2% -195.4% +65 pp
    €713.36K -95.2% -€70.41M +74.2% -9,869.6% -96 pp -€47.49M +329.1% -6,656.7% -66 pp
    €14.89M +14.4% -€40.41M -50.9% -271.5% +3.6 pp -€11.07M -80.7% -74.3% +3.7 pp
    €13.01M -12.5% -€82.25M +3.8% -632.0% -0.99 pp -€57.27M -20.7% -440.1% +0.45 pp
    €14.87M -66.0% -€79.24M +0.8% -532.9% -3.5 pp -€72.20M +34.6% -485.5% -3.6 pp
    €43.72M -30.6% -€78.62M +132.5% -179.8% -1.3 pp -€53.64M -139.6% -122.7% -3.4 pp
    €62.95M -€33.82M -53.7% €135.41M 215.1%

    Notifications